依卡派特 | 104775-36-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 依卡派特
• 中文别名: 3-(2-(3,4-二甲氧基苯乙基氨基)-2-氧代乙基氨基)-N-甲基苯甲酰胺
• 英文名称: 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl]amino-N-methylbenzamide
• 英文别名: 3-((2-((2-(3,4-dimethoxyphenyl)ethyl)amino)-2-oxoethyl)amino)-N-methylbenzamide；Ecabapide；3-[[2-[2-(3,4-dimethoxyphenyl)ethylamino]-2-oxoethyl]amino]-N-methylbenzamide
• CAS: 104775-36-2
• 化学式: C₂₀H₂₅N₃O₄
• 分子量: 371.436
• InChiKey: JTAGHJPZEDNHHA-UHFFFAOYSA-N

物化性质

• 熔点：
  93-96.5°; mp 133-134.5°
• 沸点：
  658.6±55.0 °C(Predicted)
• 密度：
  1.185±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  88.7
• 氢给体数：
  3
• 氢受体数：
  5

ADMET

代谢

Ecabapide 已知的人类代谢物包括 5-氨基-2-羟基-N-甲基苯甲酰胺、N-[2-(3,4-二甲氧基苯基)乙基]-2-氧代乙酰胺和 6-羟基-Ecabapide。

Ecabapide has known human metabolites that include 5-amino-2-hydroxy-N-methylbenzamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-2-oxoacetamide, and 6-hydroxy-ecabapide.

来源:NORMAN Suspect List Exchange

反应信息

• 作为反应物：
  描述：

  依卡派特 以 phosphate buffer 为溶剂， 反应 72.0h， 生成 N-[2-(3,4-Dimethoxyphenyl)ethyl]glyoxylamide
  参考文献：
  名称：

  Identification of major biliary and urinary metabolites of ecabapide in rats

  摘要：

  1. The structures of major biliary and urinary metabolites of ecabapide in rat were identified by comparison with authentic standards using lc-ms and H-1-nmr spectrometry.2. A major metabolite was found in the bile obtained from rat after an oral dose of C-14-ecabapide and identified as the amidaldehyde derivative. In the urine, two polar metabolites were characterized as the phenolic sulphates. Further, two lipophilic metabolites were identified as alcohol derivatives, and two others as oxamic acids.3. From these results, it was estimated that the first step in the metabolism of ecabapide in rat was oxidative N-dealkylation to produce the amidaldehyde. This amidaldehyde was further metabolized by two routes, one by reduction of the amidaldehyde into the corresponding alcohol followed by mono-demethylation and subsequent aromatic O-sulphation, the second by oxidation of the amidaldehyde into the oxamic acid followed by mono-demethylation and subsequent aromatic O-sulphation.

  DOI：

  10.3109/00498259609052500
• 作为产物：
  描述：

  2-氯-N-(2-(3,4-二甲氧基苯基)乙基)乙酰胺 、 3-氨基-N-甲基苯甲酰胺 在 calcium carbonate 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 以51%的产率得到依卡派特
  参考文献：
  名称：

  Syntheses of 2-(3,4-Dimethoxyphenyl)ethylamine Derivatives and Their Antiulcer Activities.

  摘要：

  研究人员合成了一系列 2-(3,4-二甲氧基苯基)乙胺（4）的酰基衍生物，并对其腹腔注射给大鼠以预防水浸应激诱发的胃溃疡的有效性进行了评估。其中 N-[2-（3，4-二甲氧基苯基）乙基]-2-苯氨基乙酰胺盐酸盐（15）具有显著的抗溃疡活性。对 15 的四个部分进行进一步修饰后发现，只有在苯氨基部分的 2-位或 3-位引入氨基甲酰基得到的化合物（49-51、54 和 55）才具有与先导化合物相当的抗溃疡活性。然而，除了 3-取代的贝扎酰胺衍生物 55 外，其他化合物（49-51 和 54）在口服时没有产生预防效果。苯甲酰胺氮上的烷基取代产生了 3-[[[2-（3,4-二甲氧基苯基）乙基]氨基甲酰基]甲基]氨基-N-甲基苯甲酰胺（66，DQ-2511）和相关化合物（67、70、74 和 77），这些化合物在口服剂量为 50-400 毫克/千克时都具有很强的抗溃疡活性。

  DOI：

  10.1248/cpb.40.2712

文献信息

• Prodrugs containing novel bio-cleavable linkers
  申请人：Satyam Apparao

  公开号：US20060046967A1

  公开（公告）日：2006-03-02

  The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.

  本发明提供了公式(I)的化合物或其药用可接受的盐。本发明还提供了包含一个或多个公式I的化合物或其中间体以及一个或多个药用可接受的载体、车辆或稀释剂的药物组合物。本发明进一步提供了包括制备方法和使用方法在内的前药，包括释放一氧化氮的前药、双前药和相互前药，由公式I的化合物组成。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。